SPIRIT-H2H 最终结果:Ixekizumab 对比阿达木单抗治疗未用生物制剂的银屑病关节炎 52 周疗效与安全性
SPIRIT-H2H 是一项 52 周多中心开放标签盲法评估者研究,纳入 566 例未用过生物制剂的银屑病关节炎患者,随机 1:1 接受 Ixekizumab 或阿达木单抗。第 52 周时 Ixekizumab 在同时达到 ACR50 和 PASI100 及 PASI100 方面显著优于阿达木单抗,ACR50 等肌肉骨骼结局两者相似。
要点
- 第 52 周 Ixekizumab 同时达 ACR50 和 PASI100 为 39% 对 26%,优于阿达木单抗。
- 第 52 周 PASI100 为 64% 对 41%,Ixekizumab 皮损清除更优。
- ACR50 为 49.8% 对 49.8%,两者肌肉骨骼疗效相似,安全性无新发现。
核心结论
- 在未用过生物制剂的银屑病关节炎患者中,Ixekizumab 至第 52 周在关节和皮肤同时改善方面显著优于阿达木单抗。
研究设计与样本
- SPIRIT-H2H 为 52 周多中心、随机、开放标签、盲法评估者、平行组研究,纳入 566 例未用过生物制剂的银屑病关节炎患者,1:1 随机接受 Ixekizumab 或阿达木单抗,按合并 csDMARD 使用和有无中重度斑块状银屑病分层。
主要发现
- 第 52 周 Ixekizumab 组同时达到 ACR50 和 PASI100 的比例为 39%,阿达木单抗组为 26%(p<0.001)。
- 第 52 周 Ixekizumab 组 PASI100 为 64%,阿达木单抗组为 41%(p<0.001)。
- 第 52 周 ACR50 在 Ixekizumab 组为 49.8%,阿达木单抗组为 49.8%(p=0.924),达标治疗结局、附着点炎和指趾炎缓解两组相似。
- Ixekizumab 单药治疗组第 52 周同时达到 ACR50 和 PASI100 为 38%,阿达木单抗单药组为 19%(p=0.007);PASI100 为 66% 对 35%(p<0.001)。
- Ixekizumab 的疗效不受是否合并 csDMARD 影响,Ixekizumab 与阿达木单抗均未发现新的安全性信号。
关键数值与推荐
- 主要终点为第 24 周同时达到 ACR50 和 PASI100,Ixekizumab 优于阿达木单抗。
- 第 52 周同时达到 ACR50 和 PASI100:Ixekizumab 39% 对阿达木单抗 26%(p<0.001)。
- 第 52 周 PASI100:Ixekizumab 64% 对阿达木单抗 41%(p<0.001)。
- 第 52 周 ACR50:Ixekizumab 49.8% 对阿达木单抗 49.8%(p=0.924)。
- 第 52 周单药治疗亚组同时达到 ACR50 和 PASI100:Ixekizumab 38% 对阿达木单抗 19%(p=0.007);PASI100:66% 对 35%(p<0.001)。
临床怎么用
- 对于未用过生物制剂的银屑病关节炎患者,尤其合并中重度斑块状银屑病者,Ixekizumab 可作为优先考虑以同时改善关节和皮肤。
- 合并或不合并 csDMARD 时 Ixekizumab 疗效一致,单药治疗在皮肤和联合终点上仍优于阿达木单抗单药。
局限性
- 本研究为开放标签设计,虽采用盲法评估者,但仍可能存在实施偏倚。
- 研究仅纳入未用过生物制剂的银屑病关节炎患者,结论不能直接外推至生物制剂经治人群。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: SPIRIT head-to-head (H2H) is a 52-week (Wk) trial comparing ixekizumab (IXE) with adalimumab (ADA) for simultaneous American College of Rheumatology (ACR)50 and Psoriasis Area and Severity Index (PASI)100 responses in 566 patients (distributed evenly across both groups) with psoriatic arthritis (PsA). IXE was superior to ADA for this primary end point at Wk24. We aimed to determine the final efficacy and safety results through Wk52 including a prespecified subgroup analysis of concomitant conventional synthetic disease-modifying anti-rheumatic drugs (csDMARD) use. METHODS: SPIRIT-H2H is a Wk52 multicentre, open-label, blinded-assessor study comparing IXE and ADA in bionaïve patients with PsA. Patients were randomised 1:1 to IXE or ADA with stratification by concomitant csDMARD use and presence of moderate-to-severe plaque psoriasis. Prespecified end points at Wk24 and Wk52 included musculoskeletal, psoriasis, quality-of life outcomes, subgroup analyses and safety. RESULTS: A significantly higher proportion of patients treated with IXE versus ADA simultaneously achieved ACR50 and PASI100 (39% vs 26%, p<0.001), PASI100 (64% vs 41%, p<0.001) at Wk52. Efficacy of IXE and ADA was similar at Wk52 for ACR50 (49.8% vs 49.8%, p=0.924), treat-to-target outcomes, enthesitis and dactylitis resolution. Responses to IXE were consistent irrespective of concomitant csDMARD use. Significantly more patients on IXE monotherapy versus ADA monotherapy had simultaneous ACR50 and PASI100 (38% vs 19%, p=0.007), and PASI100 responses (66% vs 35%, p<0.001) at Wk52. There were no new safety findings for IXE or ADA. CONCLUSIONS: IXE provided significantly greater simultaneous joint and skin improvement than ADA through Wk52 in bionaïve patients with PsA. IXE showed better efficacy on psoriasis and performed at least as well as ADA on musculoskeletal manifestations. IXE efficacy was consistent irrespective of concomitant csDMARD use. TRIAL REGISTRATION NUMBER: NCT03151551.
引用
- Smolen JS, Mease P, Tahir H, et al. Multicentre, randomised, open-label, parallel-group study evaluating the efficacy and safety of ixekizumab versus adalimumab in patients with psoriatic arthritis naïve to biological disease-modifying antirheumatic drug: final results by week 52. Ann Rheum Dis. 2020. PMID: 32660977. doi:10.1136/annrheumdis-2020-217372
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。